Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02846376 · ClinicalTrials.gov registry record · Phase 1
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
A Phase 1 study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02846376 is a Phase 1 study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 8 participants.
The verdict
NCT02846376, a Phase 1 study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and benefit of nivolumab, ipilimumab or the combination of nivolumab with ipilimumab given after bone marrow transplant for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2019-03-08 |
| Est. Completion | 2023-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02846376
The ClinicalTrials.gov registry entry for NCT02846376 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02846376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02846376 about?
NCT02846376 is a clinical study titled "Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant". The purpose of the study is to determine the safety and benefit of nivolumab, ipilimumab or the combination of nivolumab with ipilimumab given after bone marrow transplant for patients with acute myelogenous leukemia and myelodysplastic syndrome.
What is the current status of trial NCT02846376?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2019-03-08. Estimated completion is 2023-12-21.
What interventions are being tested in trial NCT02846376?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT02846376?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.